3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
16
Radiotherapy
15
Drug Therapy
14
Paclitaxel
13
Cisplatin
12
Carboplatin
10
Immunotherapy
9
Esophagectomy
9
Radiation
8
Fluorouracil
8
Surgical Procedures, Operative
7
Capecitabine
7
Blood Specimen Collection
7
Oxaliplatin
6
Nivolumab
6
Immune Checkpoint Inhibitors
6
Chemoradiotherapy
6
nimotuzumab
5
Trastuzumab
5
130-nm albumin-bound paclitaxel
5
sintilimab
4
camrelizumab
4
Leucovorin
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Surveys and Questionnaires
3
Endoscopy
3
Bevacizumab
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Neoplasms
×
Histamine H2 Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled